Novelties on Neuroinflammation in Alzheimer's Disease-Focus on Gut and Oral Microbiota Involvement.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and observational literature without systematic review methodology
PubMed 39457054 · doi:10.3390/ijms252011272
What was done
This narrative review synthesized recent published findings on how alterations in gut and oral microbiota contribute to neuroinflammation in Alzheimer's disease (AD) through the microbiota-gut-brain axis, focusing on cellular mechanisms, bacterial metabolites, and potential therapeutic targets.
What was found
The abstract provides a qualitative mechanistic summary without quantitative metrics or statistical values. It reports that AD is linked to alterations in gut taxa (such as *Bacteroides* and *Firmicutes*) and oral pathogens (such as *Porphyromonas gingivalis*), which correlate with altered microglial activation and cytokine production. Increased gut permeability facilitates the translocation of lipopolysaccharides (LPS) into circulation to activate central toll-like receptor 4 (TLR4) pathways. Additionally, microbial-derived amyloid peptides may contribute to amyloid-beta aggregation, whereas short-chain fatty acids (such as butyrate) display anti-inflammatory effects.
Why it matters
Synthesizes current hypotheses connecting oral and gut dysbiosis to central neuroinflammation, highlighting potential therapeutic avenues such as short-chain fatty acid modulation to slow AD pathology.
Limits
The abstract presents no original empirical data, quantitative effect estimates, or study screening counts. Because it is a narrative review, it carries inherent selection bias and does not establish whether microbiome changes are causal drivers or secondary consequences of AD progression.
Cited by
- supports Lipopolysaccharide (LPS) leaking from the gut challenges immune cells to produce inflammatory cytokines that cross to the brain and stimulate microglial cells to become neurodestructive.